Cambridge, UK, 7 November 2019: PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases, today announced the start of the PRECIOUS (Predicting Crohn’s and Colitis Outcomes in the United States) study, which it is jointly funding with the Crohn’s & Colitis Foundation.
News
Black Belt TX forms a strategic partnership with Praxis Biotech to develop new therapies targeting stress response pathways in cancer.
CAMBRIDGE, UK, NEW YORK, HOUSTON and SOUTH SAN FRANCISCO, 06 November, 2019 — Artios Pharma Limited (Artios), The University of Texas MD Anderson Cancer Center (MD Anderson) and ShangPharma Innovation (ShangPharma) today announce the in-licensing by Artios of a small-molecule ATR inhibitor programme, developed jointly by MD Anderson and ShangPharma.
A new report released today by BioBeat entitled “50 Movers & Shakers in BioBusiness 2019” includes five women from organisations based at Stevenage Bioscience Catalyst (SBC) as well as two Board members. The report highlights the top female talent in the pharma and biotech sectors within the UK.
The report focuses on the impact of individuals in five key areas, namely science, finance, collaboration, patient impact and infrastructure. The SBC-based individuals which spanned the segments are:
Cambridge, UK, 05 November: PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases, is delighted to welcome Steven S. Martin to its board.
Cambridge, UK, 04 November 2019: PhoreMost Limited, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, and Sentinel Oncology, today announce an expansion of their collaboration to accelerate the progression of SOL686, a novel allosteric Polo-like kinase 1 (PLK1) inhibitor through preclinical development and IND enabling studies for the treatment of Glioma.
Arecor strengthens management team to accelerate partnership opportunities.
Arecor Limited , the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces the appointment of Jim MacDonald-Clink as Vice President, Business Development with immediate effect.
AMSBIO has introduced human recombinant iMatrix Laminin 211 fragment for the purification and maintenance of cardiomyocytes in culture.
The Laminin family of glycoproteins are an integral part of the structural scaffolding in almost every tissue of an organism. They are secreted and incorporated into cell-associated extracellular matrices. Laminin is vital for the maintenance and survival of tissues. Defective Laminins can cause muscles to form improperly, leading to a form of muscular dystrophy, lethal skin blistering disease and defects of the kidney filter.
Just as when you sell a house you need all your ducks in a row when you hit the market, so too is preparation equally crucial for a tech start up seeking funding. Anyone looking to grow their business should attend the workshop, which will be delivered by Simon Portman, a Solicitor at Marks & Clerk. The workshop will cover:
• Good housekeeping and risk management.
• Team dynamics
• Contracts and legal matters
• Intellectual property strategy
• Pitfalls to avoid